

Cite this: *Analyst*, 2016, **141**, 371

Emerging techniques in the isolation and characterization of extracellular vesicles and their roles in cancer diagnostics and prognostics

Vijaya Sunkara,^{†a} Hyun-Kyung Woo^{†a} and Yoon-Kyoung Cho^{*b,a}

Extracellular vesicles (EVs) are cell-derived nanovesicles, present in almost all types of body fluids, which play an important role in intercellular communication and are involved in the transport of biological signals for regulating diverse cellular functions. Due to the increasing clinical interest in the role of EVs in tumor promotion, various techniques for their isolation, detection, and characterization are being developed. In this review, we present an overview of the current EV isolation and characterization methods in addition to their applications and limitations. Furthermore, EVs as the potential emerging biomarkers in cancer management and their clinical implementation are briefly discussed.

Received 29th August 2015,
Accepted 25th October 2015
DOI: 10.1039/c5an01775k
www.rsc.org/analyst

1. Introduction

Cells release several types of extracellular vesicles (EVs) including exosomes (40–120 nm in diameter, released during

the fusion of multi-vesicular endosomes with the plasma membrane), microvesicles (100–1000 nm in diameter, formed by direct budding from the plasma membrane) and apoptotic bodies (1–5 μ m in diameter, produced by cells due to apoptosis), which have been classified based on their biogenesis and size.^{1–4} However, no analysis method or specific marker is currently available to distinguish the origin of these vesicles, upon release into the extracellular matrix. Furthermore, it is difficult to differentiate between vesicles of a similar size when they have been isolated together. Different terminologies such as EVs, microvesicles, or exosomes are used synonymously,

^aDepartment of Biomedical Engineering, School of Life Sciences, Ulsan National Institute of Science and Technology (UNIST), UNIST-gil 50, Ulsan 689-798, Republic of Korea. E-mail: ykcho@unist.ac.kr

^bCenter for Soft and Living Matter, Institute for Basic Science (IBS), UNIST-gil 50, Ulsan 689-798, Republic of Korea. E-mail: ykcho@unist.ac.kr


[†]These authors contributed equally.



Vijaya Sunkara

Vijaya Sunkara is a research scientist at UNIST. She obtained her BSc in Chemistry & Biology and MSc in Organic Chemistry from Osmania University, India, in 1995 and 1998, respectively. She received her PhD in Organic Chemistry from Jawaharlal Nehru Technological University (JNTU), India, in 2004. She worked as a postdoctoral researcher (2004–2006), and a research scientist (2006–2009) at Pohang University of Science &

Technology (POSTECH) and NSBPOSTECH, Korea, respectively, where she was involved in the development of nano-scale controlled surfaces for DNA microarrays. Her current research focuses on the isolation and characterization of cancer-related biomolecules from the patients.



Hyun-Kyung Woo

Hyun-kyung Woo is currently a combined M.S. & Ph.D. student in Biomedical Engineering at UNIST. She is a recipient of 2015 Nine Bridges Fellowship. She obtained her B.S. in Chemical Engineering and Bioengineering from UNIST in 2015. Her research interests are in centrifugal microfluidic devices, lab-on-a-chip for point of care tests and cancer diagnostics.



particularly in the engineering community, for the isolated nanovesicles and there is no consensus available to discriminate these vesicles. Therefore, in this review, we will use the term "EVs" for all types of vesicles that measure <200 nm in diameter, to make the review simple and understandable.

EVs are secreted by most cell types and are present in many kinds of body fluids such as blood plasma, urine, amniotic fluid, saliva, ascites, cerebrospinal fluid *etc.*⁵ At the time of their discovery, they were thought to be involved in cellular excretion of by-products and not much attention was given to them until their participation in the immune response was revealed.^{6,7} In 2007, it was shown that they mediate communication between cells due to the presence of functional RNAs.⁸ After that, research on EVs has grown exponentially focusing on the development of new techniques for the isolation as well as analysis of their composition and physiological functions.^{4,9,10}

The functions of EVs depend on their origin as well as their composition. Because they carry diverse membrane and cytosolic proteins, DNA, mRNA and miRNA, EVs are considered potential biomarkers and are found to be involved in both normal physiological processes and disease progression in a pleiotropic manner, including the immune response, antigen presentation, cell signaling, intercellular communication *etc.*^{2,9,11–20}

In a tumor microenvironment, communication between cancer and surrounding cells is essential for the tumors to survive, metastasize and spread at distant sites (Fig. 1a). Here,



Fig. 1 Schematic representation of cell-to-cell communication through EVs and their isolation techniques. (a) EVs derived from cancer cells transfer nucleic acids and proteins to the surrounding as well as distant cells and promote niche formation, angiogenesis and metastasis. (b) Isolation of EVs based on density (ultracentrifugation, sucrose gradient techniques, and precipitation reagents), size (filtration through membranes filters) and immunoaffinity (immunomagnetic separation, microarray *etc.*).



Yoon-Kyoung Cho

Yoon-Kyoung Cho is currently an associate professor in Biomedical Engineering at UNIST and a group leader in the Center for Soft and Living Matter at the Institute for Basic Science (IBS), Republic of Korea. She received her Ph.D. in Materials Science and Engineering from the University of Illinois at Urbana-Champaign in 1999, having obtained her M.S. and B.S. in Chemical Engineering from POSTECH in 1994 and 1992, respectively. She

worked as a senior researcher (1999–2008) at Samsung Advanced Institute of Technology (SAIT), where she participated in the development of in vitro diagnostic devices for biomedical applications. Since she joined UNIST in 2008, she has been the chair of the school of Nano-Bioscience and Chemical Engineering (2008–2014) and the school of Life Sciences (2014–2015) and the director of World Class University (2009–2013) and BK21 (2013–2015) programmes. Her research interests range from basic sciences to translational research in microfluidics and nanomedicine. Current research topics include a lab-on-a-disc for the detection of rare cells and biomarkers, quantitative analysis of single cells, and system analysis of cellular communication.

EVs play a vital role to transfer the tumor related genetic information to the surrounding as well as distant cells and promote tumor progress through metastatic niche formation, tumor stroma generation and angiogenesis.^{9,11,20–24}

In cancer research, intercellular communication through miRNA is of particular interest, as they can regulate the gene expression in recipient cells.^{25–32} However, the amount of miRNA from EVs and its clinical importance remain a matter of debate.^{23,33} In the literature, it is still not clear which miRNA, the free miRNA or the exosomal miRNA, contributes to a greater extent. Nonetheless, the advantage of isolating and analyzing the exosomal RNAs is that the lipid bilayer protects these molecules from degradation and allows efficient recovery from biological fluids.^{34,35}

Isolation and analysis of pure EVs further enhance our understanding of their roles in numerous biological events. As EVs are gaining importance as biomarkers of tumor signatures, their isolation with high purity is necessary, or else their analysis could yield misleading results owing to the presence of contaminants such as viruses, lipoproteins, large protein aggregates, and other vesicles. Differential ultracentrifugation is the conventional and most widely used method for the isolation of different vesicles from bio-fluids. However, it requires a long time for isolation and different particles with similar physical properties can co-sediment. Thus, to overcome these limitations, sucrose gradient purification and precipitation reagents were developed. Numerous groups have been working



on developing microfluidic devices for the efficient isolation of pure EVs from bio-fluids.¹⁰

The size of EVs is much below the resolution of conventional fluorescence microscopes. Therefore, specialized equipment is needed for the detection and analysis of the physical characteristics of the EVs. At the same time, characterizing the exosomal content is very important for understanding biological functions of EVs as well as their roles in cancer development. Several techniques are available and a combination of different methods is now being used for specific EV analysis.³⁶ Recent reviews discuss EVs as an emerging biomarker for intercellular communication and medical diagnostics.^{4,12–15} In addition, the advances in isolation technologies of exosomes using micro and nanofluidic devices were reviewed recently.^{10,37} However, Liga *et al.* mainly focused on various isolation techniques whereas Ko *et al.* reviewed the isolation as well as detection methods, but the surface marker and protein analysis was not discussed in detail. Here, we will focus on recent trends in EV isolation and detection along with the surface characterization methods and their roles in cancer diagnostics and prognostics.

2. EV isolation methods

With the growing interest in EVs as potential biomarkers, various isolation techniques have recently been developed.¹⁰ Furthermore, several research groups compared the efficiency of available isolation techniques.^{38–40} Based on the principle of their separation, the methods can be categorized into three major classes: density-, size-, and immunoaffinity-based iso-

lation. Here, we have summarized the common isolation techniques and recent trends along with new approaches.


2.1 Density-based isolation

As the name suggests, based on their density, particles are separated upon centrifugation. The techniques include ultracentrifugation and regular centrifugation with precipitation reagents including commercialized kits (Fig. 1b, left). These techniques enable the concentration of EVs rather than isolation.

2.1.1 Ultracentrifugation (UC). Particles are separated by applying differential centrifugation by varying the *g* force. Cells and cellular debris are removed at a low *g* force; however, a high *g* force of ~200 000*g* sediments the EVs (1.13–1.19 g mL⁻¹).^{11,41} UC is a conventional and most commonly used method for isolating EVs. However, it takes ~5 h for isolating the exosomal pellet;^{5,42} moreover, it requires special equipment, an ultracentrifuge, which might be unavailable in common laboratories in clinical settings. Other drawbacks include inefficient isolation and low recovery.^{38–40} Therefore, sucrose gradient centrifugation has been developed to improve the purity and recovery.³⁸ Nevertheless, it cannot separate impurities like viruses⁴³ and also it is time-consuming owing to complicated sample-processing steps with differential centrifugation.

2.1.2 Precipitation reagents. Recently, numerous commercial kits that include precipitation reagents have been made available for EV isolation. Here, the reagents reduce the solubility by lowering the hydration of EVs and lead to precipitation. Using these kits, EVs can be separated at a low *g* force and with higher yield than UC. However, these kits are too expensive to be widely used and give low purity due to co-precipi-

(a) RNA analysis using qPCR



(b) RNA and protein analyses using electrochemical sensor



(c) Protein analysis using photosensitizer beads



(d) Protein analysis using SPRI



Fig. 2 Devices for EV isolation and analysis. (a) RNA analysis using qPCR.⁵⁸ (b) RNA and protein analysis using an electrochemical sensor.⁵⁹ (c) Protein analysis using photosensitizer beads.⁶⁰ (d) Protein analysis using SPRI.⁴² Reproduced from ref. 42 and 58–60 with permission from the Nature Publishing Group, Elsevier, and American Chemical Society.



tation of proteins and EVs, as the solubility of almost all particles including EVs and proteins decreases equally when using these materials.⁴⁴ Moreover, the principles underlying the mechanisms of these kits are unknown and some of the kits have a very long incubation time of up to 12 h.³⁹ In a comparative study, commercial kits such as Exo-Spin, Invitrogen, and ExoQuick were found to have a higher recovery than UC, while the PureExo kit has a recovery similar to that of UC.^{40,45} More recently, Shin *et al.* used polyethylene glycol and a dextran aqueous two-phase system (ATPS) to isolate EVs.⁴⁶

2.2 Size-based isolation

With exosomal size being known (<200 nm), EVs can be separated from cells and large debris by using nano-sized membrane filters (Fig. 1b, middle). Filtration is an effective method for the removal of large debris including large vesicles (above 200 nm in diameter), sub-cellular fractions, protein aggregates, protein–nucleic acid aggregates, or plasma proteins.⁴⁷ Membranes with pore sizes of 0.2, 0.22, and 0.45 μm and materials such as polyvinylidene fluoride⁴⁸ and track-etched polycarbonate are widely used to remove large debris.^{49,50} The size based isolation techniques also enrich the EVs from a complex mixture of samples but do not isolate them specifically.

To enhance the purity, a combination of filtration and UC is also commonly used.^{23,51–53} Muller *et al.* reported that this combined method is better than using a UC based method, differential centrifugation or the sucrose density gradient method alone.⁴⁷ Davies *et al.* applied the combined method with pressure- and electrophoresis driven filtration for isolating and purifying EVs.⁵⁴

2.2.1 Other approaches. Apart from membrane filtration, several other approaches were proposed for size-based separation of EVs including acoustic waves and micro pillar-based methods. Santana *et al.* used geometry to separate vesicles by using the principles of deterministic lateral displacement (DLD).⁵⁵ Lee *et al.* used acoustic waves to isolate EVs in a contact-free manner.⁵⁶ Wang *et al.* used ciliated micro pillars which possessed porous silicon nanowires on the sidewalls, for multi-scale filtration by removing cellular debris as well as proteins and other small objects.⁵⁷

2.3 Affinity-based isolation

To isolate EVs and study their relationship with cancer, new isolation techniques utilizing microfluidics including paper-based microfluidic devices, immunomagnetic beads, photosensitizer beads *etc.* are being developed, based on immunoaffinity capture with antibodies specific to EVs (Fig. 1b, right).^{38,49,61–64} The common exosomal markers are tetraspansins including CD9, CD63, and CD81 and tumor-associated markers are epithelial cell adhesion molecules (EpCAM), IGF-1R α units (α -IGF-1R), CA125, CD41b, and E-cadherin.^{42,65} With the markers specific to exosomes, these methods aid in the specific isolation of exosomes depending on the capture antibodies used.

Various microfluidic devices are developed for selective isolation and analysis on a single device by using a small sample volume and within a short period of time. Due to their simplicity, these techniques can be applied to point of care (POC) diagnostics. The microfluidic chip shown in Fig. 2a uses magnetic microbeads (3 μm in diameter) coated with anti-EGFR to capture EVs from 100 μL of serum and has >93% capture efficiency. It is an integrated method from EV isolation to RNA analysis by qPCR in a single chip, which can be completed within 2 h.⁵⁸ Electric field-induced release and measurement (EFIRM) was used for disrupting exosomes and monitoring the released RNA/protein biomarkers, after capturing the EVs by using anti-CD63-magnetic beads (Fig. 2b). With this device and *in vivo* experiments, the authors confirmed that the H460-CD63-GFP shed exosomes were transported to blood and saliva.⁵⁹ In another approach, He *et al.* used magnetic beads coated with anti-EpCAM and anti-CA125 to isolate EVs in volumes as low as 30 μL of plasma. It is an integrated analysis technique including exosome capture and protein detection using chemi-fluorescence in a single chip.⁶⁵ Yoshioka *et al.* used photosensitizer-beads to capture CD147- and CD9-positive EVs from 5 μL of serum, as shown in Fig. 2c. They could complete EV capture and analysis within 1.5 h by using Exo-Screen.⁶⁰ Zhu *et al.* used an antibody microarray with surface plasmon resonance imaging (SPRi) to capture and detect tumor-derived EVs in real time and in a label-free manner, as shown in Fig. 2d.⁴²

Apart from the above techniques, the methods used for the separation of nanoparticles have a high potential to be used in the isolation of EVs from a complex mixture of samples. For example, the Heller group developed a dielectrophoretic method for the recovery of drug delivery nanoparticles as well as cancer related biomarkers from plasma and blood.^{66,67} This approach can be used for the isolation and detection of EVs as well.

3. Detection and downstream analysis of EVs

Novel detection methods are required to explore the physical characteristics and biology of EVs. To analyze them, a combination of different optical and non-optical techniques is utilized, including electron microscopy, light scattering, fluorescence, and molecular profiling. Here, we have summarized the most commonly used methods, their applicability, and limitations.

3.1 Size characterization

Size and morphological information can be obtained from high-resolution imaging with electron microscopy utilizing transmission electron microscopy (TEM), scanning electron microscopy (SEM),⁷⁰ or atomic force microscopy (AFM) (Fig. 3a). The light scattering techniques (Fig. 3b–d) determine the relative size distribution in a solution, the concentration, and the zeta potential of the particles.



Physical characterization of EVs



Fig. 3 Characterization of EVs. (a) Evaluation of morphology by transmission electron microscopy (TEM)²³ and (b) size distribution and concentration by nanoparticle tracking analysis (NTA),²³ (c) size distribution by dynamic light scattering (DLS),⁴⁹ (d) zeta potential measurements,⁶⁸ (e) enzyme-linked immunosorbent assay (ELISA),⁶⁰ (f) western blotting (WB),⁶⁵ (g) Bradford assay for total protein quantification (BCA) of EVs from non-small-cell lung cancer (NSCLC) patients and healthy people,⁶⁵ and (h) flow cytometry (FC).⁶⁹ Reproduced from ref. 23, 49, 60, 65, 68, and 69 with permission from Elsevier, Nature Publishing Group, Royal Society of Chemistry and Japan Society of Applied Physics.

3.1.1 TEM. Electron microscopy provides information on the size and structure of the EVs. In most cases, concentrated suspensions of EVs are applied and fixed on the grids. TEM is usually combined with immunogold particles to detect EVs specifically (Fig. 3a).²³ It is a valuable tool to assess the size, morphology, and presence of surface markers; however, the concentration of EVs cannot be measured using this technique.

3.1.2 AFM. AFM provides information regarding surface features and has been used to assess the morphology of EVs. Like TEM, AFM cannot be used for measuring the concentration of EVs.⁷¹

3.1.3 Nanoparticle tracking analysis (NTA). It is a particle tracking method for measuring the EV concentration and size distribution.⁷² A laser beam is scattered by the particles in the sample solution, and the mean velocity of each particle is calculated on the basis of the Stokes–Einstein equation. The procedure for NTA analysis was optimized to minimize the sources of errors.^{41,73} NTA was also used for the analysis of fluorescently labeled EVs, derived from the blood of ovarian cancer patients.⁷⁴ Prior to NTA analysis, isolation and purification are required to remove other particles that may have a

similar size. Using this technique, the vesicles with similar Brownian motion cannot be distinguished from EVs and the concentration calculated by this technique could include a mixture of different particles along with EVs. However, currently, this is the most widely used method for analyzing the size and concentration of EVs (Fig. 3b). From NTA analysis, it was shown that breast cancer patients secrete higher concentration of EVs than healthy donors.²³

3.1.4 Dynamic light scattering (DLS). DLS is used for measuring the size distribution⁴⁹ and zeta potential of the EVs (Fig. 3c and d). The principle of measuring the size is based on the Brownian motion of the particles in solution; particles diffuse at a speed related to their size; the smaller the particle, the faster it moves. The particles in solution are illuminated with a laser, and light scattering by the particles at a specific angle is detected and the intensity changes are analyzed to determine the size and its distribution. The diffusion rate of the particles depends on the temperature; hence, care must be taken to analyze all the samples at a constant temperature.

Zeta potential indicates the relative stability of the particles in solution.⁷⁷ It is determined by measuring their velocity during the electrophoresis. Charged particles migrate towards



the electrode under an applied electric field. The speed of the particles is proportional to the field strength and the zeta potential. The value of the zeta potential depends on the temperature, pH, conductivity, and salt concentration of the buffer used.

DLS analysis gives the average size of relatively mono-disperse populations of isolated EVs, and it may not be a good choice for a heterogeneous mixture of EVs. No difference was observed between the average sizes of EVs derived from cancer cells compared to those of EVs derived from normal cells. However, the EVs derived from cancer cells showed higher zeta potential than those derived from normal cells when measured using an on-chip micro capillary electrophoresis system (Fig. 3d).⁶⁸

3.2 Surface markers and protein analysis

Several methods including ELISA, western blotting, Bradford's assay, and flow cytometry provide information on the presence of proteins and specific surface markers (Fig. 3e–h). However, standardization and optimization of the protocols are necessary before being adapted for the analysis.

3.2.1 Enzyme-linked immunosorbent assay (ELISA). ELISA-based techniques provide information on the presence of surface markers and could be an indirect method to quantify exosomal proteins. Recently, various commercially available ELISA kits were used to validate EV protein content. This

is a highly sensitive method for the quantitative analysis of exosomal proteins (Fig. 3e).⁶⁰ However, it is difficult to find specific antibody sets for each type of EV and this requires several optimizations.

3.2.2 Western blotting (WB). Western blotting is a convenient method to show the presence of exosomal proteins.^{50,65} Surface markers include tetraspanins (CD9, CD63, CD81, CD82), MHC molecules, and cytosolic proteins or cytoskeletal proteins. Isolated EVs are lysed, and the proteins are separated and analyzed. WB alone cannot determine the presence of EVs. However, it is very useful for identifying proteins in purified exosomal samples (Fig. 3f).

3.2.3 Bradford assay. The total protein content of the purified EVs could be determined by the Bradford assay, which provides an estimate of the amount of EVs secreted by the cells. This technique cannot be applied for samples containing other protein contaminants and needs extra purification steps to remove contaminants. However, it is a very good tool to differentiate between the total protein contents of EVs derived from cancer patients and those derived from normal donors. The EVs released from non-small-cell lung cancer (NSCLC) patients showed higher protein content than those released from healthy people (Fig. 3g).⁶⁵

3.2.4 Flow cytometry (FC). This technique is applicable for both qualitative and quantitative characterizations of EVs (Fig. 3h).^{69,83,84} Standard FC detects vesicles above 200 nm;




Fig. 4 EVs in a tumor microenvironment and their protein/miRNA analysis for cancer diagnosis and prognosis. (a) Fluorescence images of cells producing GFP-labelled EVs and their uptake by recipient cells.⁷⁵ (b) Molecular profiling of protein markers.⁴⁹ (c) (i & ii) Detection and prognosis of miR1246 in esophageal squamous cell carcinoma (ESCC).⁷⁶ (iii & iv) Detection and prognosis of miR-19a expression in colorectal cancer (CRC).³² Reproduced from ref. 32, 49, 75 and 76 with permission from Elsevier and the Nature Publishing Group.

therefore, it cannot analyze the EVs directly. To overcome this limitation EVs are fixed on large beads, labeled with fluorophore-conjugated antibodies, and then analyzed by FC. Analysis by fixing them on beads provides information on the relative presence of surface proteins and does not quantify the amount of EVs. Lacroix *et al.* reviewed the technical improvements proposed to overcome the limitations of FC measurement.⁸⁵ Thus, it is a powerful technique to analyze EVs but the interpretation should be made cautiously by considering its limitations.

3.2.5 Miscellaneous techniques. A few techniques such as surface plasmon resonance,⁸⁶ fluorescence fluctuation spectroscopy,⁸⁷ the nanoplasmonic assay,⁸⁸ tunable resistive pulse sensing,⁸⁹ electrohydrodynamic induced nanoshearing,⁹⁰ and EFIRM⁵⁹ were used for the sensitive detection of EVs. In addition, the use of special techniques such as micro-nuclear magnetic resonance, resistive pulse sensing, Raman microspectroscopy, small-angle X-ray scattering *etc.* for the detection of EVs was reviewed recently.³⁶ However, each technique needs to be validated for its application in the detection of specific EVs.

3.3 Molecular analysis

3.3.1 Fluorescence imaging. Given the information that cancer cell derived EV has a role in metastatic niche formation, tracking their intercellular communication may contribute to understanding the mechanism of tumor progression and metastasis (Fig. 4a). To trace EVs, a lipophilic dye for capturing a lipid bilayer of EV or a fluorescent probe fused with EV specific protein markers is useful. Lipophilic carbocyanines including PKH67, PKH26, DiI and DiR and the green fluorescent protein (GFP) or red fluorescent protein (RFP) tagged exosomal marker CD63 are widely used for *in vivo* and *in vitro* imaging.^{75,91} Zomer *et al.* used *in vivo* imaging to study migratory behavior and metastatic capacity through uptake of EV.⁹¹

3.3.2 Molecular profiling. It has been reported that EVs contain protein and diverse RNA cargo including short sequences of 20–200 nt (like miRNA and fragments of mRNA) and longer species like 18S and 28S rRNA.⁹⁷ Molecular profiling of these components has been used to examine their relationship with cellular origin and their application in cancer diagnostics.^{49,58}

Table 1 Clinical importance of exosomal miRNA in cancers

Cancer types	Sample type	EV isolation method	RNA isolation	Exosomal contents (miRNA)	Clinical value
Esophageal squamous cell carcinoma (ESCC) Colorectal cancer (CRC)	Serum	Ultracentrifugation (100 000g)	TRIzol reagent, mirVana PARIS kit	miR-1246	Upregulation in patients ⁷⁶
	Serum	0.45 µm filtration, ExoQuick	mirVana microRNA isolation kit (Life Tech)	miR-21	Upregulation in patients than benign disease ⁴⁸
	Serum	Ultracentrifugation (100 000g)	Acid-guanidine-phenol-chloroform	miR-19a and 92a	Upregulation in patients. Higher expression is indicative of poor prognosis ³²
	Serum	0.2 µm filtration, ultracentrifugation (120 000g)	TRIzol reagent (Invitrogen), RNeasy Mini spin column (Qiagen), Agilent miRNA labeling reagent	Let-7a, miR-1229, 1246, 150, 21, 223, 23a	Upregulation in patients ²⁶
Hepato-cellular carcinoma (HCC)	Serum	0.22 µm filtration, ultracentrifugation (100 000g)	miRNeasy Mini Kit (Qiagen)	miR-718 (tumor-suppressive miRNA)	Progression and recurrence. Downregulation in patients with recurrence compared to that observed in those without recurrence ⁷⁸
	Serum	Total exosome isolation reagent (Invitrogen)	Isothiocyanate-phenol/chloroform extraction procedures	miR-21	Upregulation in patients compared to that observed in patients with hepatitis or in healthy controls ⁷⁹
Breast cancer	Serum	ExoQuick exosome precipitation solution (BioCat)	mirVana PARIS kit (Life Tech)	miR-101, 372, 373	Upregulation in patients ⁸⁰
Cervical cancer	Cervicovaginal lavages	Ultracentrifugation	mirVana microRNA isolation kit (Ambion)	miR-21, 146a	Upregulation in patients ²⁹
Pancreatic cancer	Serum	Sucrose-gradient centrifugation (100 000g)	miRNeasy Mini Kit (Qiagen)	miR-1246, 4644, 3976, 4306	Upregulation in patients ⁸¹
Prostate cancer	Plasma	ExoQuick exosome precipitation solution (SBI)	miRNeasy Micro Kit (Qiagen)	miR-1290, miR-375	Upregulation in patients. Their levels are associated with a poor survival rate ⁸²



Table 2 Clinical importance of exosomal protein markers in cancers

Cancer types	Sample type	EV isolation method	Protein assay	Exosomal contents (protein)	Clinical value
Pancreatic cancer	Serum	0.2 μ m filtration, ultracentrifugation (150 000g)	Ultra-performance liquid chromatography-mass spectrometry (UPLC-MS)	Glypican-1 (GPC1)	100% sensitivity and specificity for detecting pancreatic cancer ⁹²
	Saliva	Magnetic beads based capture	Western blotting	Apbb1p, Daf2, Foxp1, Incenp, BCO31781, Aspn, and Gng2	Upregulation in pancreatic cancer-derived exosomes from tumor-bearing mice ⁹³
Acute myeloid leukemia (AML)	Plasma	0.22 μ m filtration, Bio-Gel A50 m columns (Bio-Rad), ultracentrifugation (100 000g)	Immunoaffinity capture	CD34	Upregulation in patients ⁹⁴
Colon cancer	Serum	Immunoaffinity capture	ExoScreen	CD147, CD9	Upregulation of double positive (both CD147 and CD9) in patients ⁶⁰
Prostate cancer	Plasma	Ultracentrifugation (100 000g)	Western blotting	Phosphatase and tensin homolog (PTEN)	Only detected in cancer patients ⁹⁵
Bladder cancer	Urine	0.2 μ m filtration, ultracentrifugation (100 000g)	Western blotting	EDIL-3/Del1	Upregulation in patients associated with tumor grade ⁹⁶

Quantitative reverse transcription polymerase chain reaction (qRT-PCR), miRNA arrays, bioanalyzers and mass spectrometry are widely used for profiling exosomal cargo.^{45,97,98} Wyss *et al.* used single fluctuation analysis to profile both the size and the relative expression level of a particular membrane receptor in individual EV.⁸⁷ Rekker *et al.* compared isolation methods for microRNA profiling, showing that both UC and ExoQuick precipitation methods are suitable for profiling.⁴⁵

Im *et al.* conducted molecular profiling of ovarian cancer protein markers, as shown in Fig. 4b. Through this, ovarian cancer cells and benign cells could be differentiated from each other.⁴⁹ Ueda *et al.* established mass spectrometric immunoassay monolith pipette tips to profile serum EV, identifying CD91 as a lung adenocarcinoma specific antigen on EV.⁹⁸

3.3.3 Clinical analysis. Clinical analysis of EVs has increased recently because it is an enriched source of biomarkers containing nucleic acids (Table 1) and proteins (Table 2) for diagnosing cancer. Especially, Melo *et al.* detected pancreatic cancer with an area under the curve (AUC) of 1.0 (sensitivity and specificity of 100%) using Glypican-1 which is membrane protein specifically enriched in cancer-cell derived EVs.⁹² Yoshioka *et al.* detected colon cancer with an AUC of 0.820 using double positive of CD147/CD9 EV.⁶⁰ Gabriel *et al.* detected prostate cancer using tumor suppressor phosphatase and tensin homolog (PTEN) which is expressed only in the EVs from the plasma of patients.⁹⁵ Ueda *et al.* detected lung adenocarcinoma with an AUC of 0.724 (sensitivity: 60.0% and specificity: 89.0%) using exosomal CD91 and with an AUC of 0.882 (sensitivity: 71.4% and specificity: 91.8%) using a combination of CEA (classical biomarker) and exosomal CD91.⁹⁸ With receiver operating characteristic curve analysis of miR-1246 (Fig. 4c (i)), esophageal squamous cell carcinoma (ESCC) can be detected, with AUC = 0.754 (sensitivity: 71.3% and specificity: 73.9%).⁷⁶ The expression levels of miR-19a are studied at

different stages of cancer for diagnosing colorectal cancer (CRC) as shown in Fig. 4c (iii).³² In addition, they have a prognostic value in each case, providing a lower survival rate with higher miRNA expression (Fig. 4c (ii) and (iv)).^{32,76}

4. Conclusions and perspectives

EVs contain a substantial amount of genetic information that could be transferred to other cells, thereby promoting the progression of metastatic tumors in cancer patients. Several methods are being developed to isolate and analyze EVs to understand their physiological functions. However, still there is a need for new technologies that could isolate pure EVs from a mixture of various particles and contaminants.

One of the biggest issues in the EV research is the lack of proper terminology and methodology. Though we termed all vesicles as EVs in this article, there should be a clear demarcation for each vesicle and the data regarding their content, specific markers and physiological functions should be obtained and compared for different kinds of vesicles.

Another major issue in this field is differentiating between microvesicles and exosomes of similar size. Any vesicles that share size, density, or scattering properties would interfere with the isolation and detection of other vesicles. Devices that specifically capture a particular type of vesicles should be developed.

In addition, efficiency in terms of purification and quantification of the currently available isolation procedures is unknown. A standard must be developed to compare the data of different sets of experiments.

Apart from all these issues, demonstrating the physiological functions of EVs *in vivo* is a major challenge. Thus far, data regarding EVs have been obtained from *in vitro* studies and very little is known about their function *in vivo*. Nevertheless,



increasing evidence suggests that EVs are emerging biomarkers for cancer diagnosis and therapeutics.

Acknowledgements

This work was supported by the National Research Foundation (NRF) grants (2013R1A2A2A05004314, 2012R1A1A2043747), a grant from the Korean Health Technology R&D Project, the Ministry of Health & Welfare (A121994) and IBS-R020-D1 funded by the Korean Government.

References

- G. Raposo and W. Stoorvogel, *J. Cell Biol.*, 2013, **200**, 373–383.
- V. R. Minciaccchi, M. R. Freeman and D. Di Vizio, *Semin. Cell Dev. Biol.*, 2015, **40**, 41–51.
- J. Kowal, M. Tkach and C. Théry, *Curr. Opin. Cell Biol.*, 2014, **29**, 116–125.
- S. E. Andaloussi, I. Mäger, X. O. Breakefield and M. J. Wood, *Nat. Rev. Drug Discovery*, 2013, **12**, 347–357.
- K. W. Witwer, E. I. Buzás, L. T. Bemis, A. Bora, C. Lässer, J. Lötvall, E. N. Nolte-’t Hoen, M. G. Piper, S. Sivaraman, J. Skog, C. Théry, M. H. Wauben and F. Hochberg, *J. Extracell. Vesicles*, 2013, **2**, 20360.
- G. Raposo, H. W. Nijman, W. Stoorvogel, R. Liejendekker, C. V. Harding, C. J. Melief and H. J. Geuze, *J. Exp. Med.*, 1996, **183**, 1161–1172.
- L. Zitvogel, A. Regnault, A. Lozier, J. Wolfers, C. Flament, D. Tenza, P. Ricciardi-Castagnoli, G. Raposo and S. Amigorena, *Nat. Med.*, 1998, **4**, 594–600.
- H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee and J. O. Lötvall, *Nat. Cell Biol.*, 2007, **9**, 654–659.
- L. Brinton, H. Sloane, M. Kester and K. Kelly, *Cell. Mol. Life Sci.*, 2015, **72**, 659–671.
- A. Liga, A. D. B. Vliegenthart, W. Oosthuyzen, J. W. Dear and M. Kersaudy-Kerhoas, *Lab Chip*, 2015, **15**, 2388–2394.
- X. Zhang, X. Yuan, H. Shi, L. Wu, H. Qian and W. Xu, *J. Hematol. Oncol.*, 2015, **8**, 1–13.
- E. I. Buzas, B. Gyorgy, G. Nagy, A. Falus and S. Gay, *Nat. Rev. Rheumatol.*, 2014, **10**, 356–364.
- C. Soekmadji, P. Russell and C. Nelson, *Cancers*, 2013, **5**, 1522–1544.
- A.-K. Ludwig and B. Giebel, *Int. J. Biochem. Cell Biol.*, 2012, **44**, 11–15.
- P. Kharaziha, S. Ceder, Q. Li and T. Panaretakis, *Biochim. Biophys. Acta, Rev. Cancer*, 2012, **1826**, 103–111.
- T. Katsuda, N. Kosaka and T. Ochiya, *Proteomics*, 2014, **14**, 412–425.
- J. Rak and A. Guha, *BioEssays*, 2012, **34**, 489–497.
- A. V. Vlassov, S. Magdaleno, R. Setterquist and R. Conrad, *Biochim. Biophys. Acta, Gen. Subj.*, 2012, **1820**, 940–948.
- A. L. S. Revenfeld, R. Bæk, M. H. Nielsen, A. Stensballe, K. Varming and M. Jørgensen, *Clin. Ther.*, 2014, **36**, 830–846.
- Y. Sun and J. Liu, *Clin. Ther.*, 2014, **36**, 863–872.
- Y. Zhang and X.-F. Wang, *Nat. Cell Biol.*, 2015, **17**, 709–711.
- B. Costa-Silva, N. M. Aiello, A. J. Ocean, S. Singh, H. Zhang, B. K. Thakur, A. Becker, A. Hoshino, M. T. Mark and H. Molina, *Nat. Cell Biol.*, 2015, **17**, 816–826.
- S. A. Melo, H. Sugimoto, J. T. O’Connell, N. Kato, A. Villanueva, A. Vidal, L. Qiu, E. Vitkin, L. T. Perelman and C. A. Melo, *Cancer Cell*, 2014, **26**, 707–721.
- A. Azmi, B. Bao and F. Sarkar, *Cancer Metastasis Rev.*, 2013, **32**, 623–642.
- M. Ono, N. Kosaka, N. Tominaga, Y. Yoshioka, F. Takeshita, R.-u. Takahashi, M. Yoshida, H. Tsuda, K. Tamura and T. Ochiya, *Sci. Signaling*, 2014, **7**, 63.
- H. Ogata-Kawata, M. Izumiya, D. Kurioka, Y. Honma, Y. Yamada, K. Furuta, T. Gunji, H. Ohta, H. Okamoto and H. Sonoda, *PLoS One*, 2014, **9**, e92921.
- S. Rana, K. Malinowska and M. Zöller, *Neoplasia*, 2013, **15**, 281–295.
- D. M. Cereghetti and P. P. Lee, *Microna*, 2013, **2**, 194–204.
- J. Liu, H. Sun, X. Wang, Q. Yu, S. Li, X. Yu and W. Gong, *Int. J. Mol. Sci.*, 2014, **15**, 758–773.
- B. N. Hannafon and W.-Q. Ding, *Int. J. Mol. Sci.*, 2013, **14**, 14240–14269.
- I. Hoshino and H. Matsubara, *Surg. Today*, 2013, **43**, 467–478.
- T. Matsumura, K. Sugimachi, H. Iinuma, Y. Takahashi, J. Kurashige, G. Sawada, M. Ueda, R. Uchi, H. Ueo and Y. Takano, *Br. J. Cancer*, 2015, **115**, 275–281.
- J. R. Chevillet, Q. Kang, I. K. Ruf, H. A. Briggs, L. N. Vojtech, S. M. Hughes, H. H. Cheng, J. D. Arroyo, E. K. Meredith, E. N. Gallichotte, E. L. Pogossova-Agadjanyan, C. Morrissey, D. L. Stirewalt, F. Hladik, E. Y. Yu, C. S. Higano and M. Tewari, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 14888–14893.
- Q. Li, Y. Shao, X. Zhang, T. Zheng, M. Miao, L. Qin, B. Wang, G. Ye, B. Xiao and J. Guo, *Tumor Biol.*, 2015, **36**, 2007–2012.
- Q. Ge, Y. Zhou, J. Lu, Y. Bai, X. Xie and Z. Lu, *Molecules*, 2014, **19**, 1568–1575.
- E. van der Pol, F. Coumans, Z. Varga, M. Krumrey and R. Nieuwland, *J. Thromb. Haemostasis*, 2013, **11**, 36–45.
- J. Ko, E. Carpenter and D. Issadore, *Analyst*, 2015, DOI: 10.1039/C5AN01610J.
- B. J. Tauro, D. W. Greening, R. A. Mathias, H. Ji, S. Mathivanan, A. M. Scott and R. J. Simpson, *Methods*, 2012, **56**, 293–304.
- J. Caradec, G. Kharmate, E. Hosseini-Beheshti, H. Adomat, M. Gleave and E. Guns, *Clin. Biochem.*, 2014, **47**, 1286–1292.
- R. E. Lane, D. Korbie, W. Anderson, R. Vaidyanathan and M. Trau, *Sci. Rep.*, 2015, **5**, 7639.
- W. Oosthuyzen, N. E. Sime, J. R. Ivy, E. J. Turtle, J. M. Street, J. Pound, L. E. Bath, D. J. Webb, C. D. Gregory and M. A. Bailey, *J. Physiol.*, 2013, **591**, 5833–5842.
- L. Zhu, K. Wang, J. Cui, H. Liu, X. Bu, H. Ma, W. Wang, H. Gong, C. Lausted and L. Hood, *Anal. Chem.*, 2014, **86**, 8857–8864.



- 43 R. Cantin, J. Diou, D. Bélanger, A. M. Tremblay and C. Gilbert, *J. Immunol. Methods*, 2008, **338**, 21–30.
- 44 D. H. Atha and K. C. Ingham, *J. Biol. Chem.*, 1981, **256**, 12108–12117.
- 45 K. Rekker, M. Saare, A. M. Roost, A.-L. Kubo, N. Zarovni, A. Chiesi, A. Salumets and M. Peters, *Clin. Biochem.*, 2014, **47**, 135–138.
- 46 H. Shin, C. Han, J. M. Labuz, J. Kim, J. Kim, S. Cho, Y. S. Gho, S. Takayama and J. Park, *Sci. Rep.*, 2015, **5**, 13103.
- 47 L. Muller, C.-S. Hong, D. B. Stolz, S. C. Watkins and T. L. Whiteside, *J. Immunol. Methods*, 2014, **411**, 55–65.
- 48 Y. Tanaka, H. Kamohara, K. Kinoshita, J. Kurashige, T. Ishimoto, M. Iwatsuki, M. Watanabe and H. Baba, *Cancer*, 2013, **119**, 1159–1167.
- 49 H. Im, H. Shao, Y. I. Park, V. M. Peterson, C. M. Castro, R. Weissleder and H. Lee, *Nat. Biotechnol.*, 2014, **32**, 490–495.
- 50 J. Rho, J. Chung, H. Im, M. Liong, H. Shao, C. M. Castro, R. Weissleder and H. Lee, *ACS Nano*, 2013, **7**, 11227–11233.
- 51 M. Kanada, M. H. Bachmann, J. W. Hardy, D. O. Frimannson, L. Bronsart, A. Wang, M. D. Sylvester, T. L. Schmidt, R. L. Kaspar and M. J. Butte, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, E1433–E1442.
- 52 W. Xue, J. E. Dahlman, T. Tammela, O. F. Khan, S. Sood, A. Dave, W. Cai, L. M. Chirino, G. R. Yang and R. Bronson, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, E3553–E3561.
- 53 L. Cecilia, E. Maria and L. Jan, *J. Visualized Exp.*, 2012, **59**, e3037.
- 54 R. T. Davies, J. Kim, S. C. Jang, E.-J. Choi, Y. S. Gho and J. Park, *Lab Chip*, 2012, **12**, 5202–5210.
- 55 S. M. Santana, M. A. Antonyak, R. A. Cerione and B. J. Kirby, *Biomed. Microdevices*, 2014, **16**, 869–877.
- 56 K. Lee, H. Shao, R. Weissleder and H. Lee, *ACS Nano*, 2015, **9**, 2321–2327.
- 57 Z. Wang, H.-j. Wu, D. Fine, J. Schmulen, Y. Hu, B. Godin, J. X. Zhang and X. Liu, *Lab Chip*, 2013, **13**, 2879–2882.
- 58 H. Shao, J. Chung, K. Lee, L. Balaj, C. Min, B. S. Carter, F. H. Hochberg, X. O. Breakefield, H. Lee and R. Weissleder, *Nat. Commun.*, 2015, **6**, 6999.
- 59 F. Wei, J. Yang and D. T. W. Wong, *Biosensors and Bioelectronics*, 2013, **44**, 115–121.
- 60 Y. Yoshioka, N. Kosaka, Y. Konishi, H. Ohta, H. Okamoto, H. Sonoda, R. Nonaka, H. Yamamoto, H. Ishii and M. Mori, *Nat. Commun.*, 2014, **5**, 3591.
- 61 S. S. Kanwar, C. J. Dunlay, D. M. Simeone and S. Negrath, *Lab Chip*, 2014, **14**, 1891–1900.
- 62 M. Jørgensen, R. Bæk, S. Pedersen, E. K. Søndergaard, S. R. Kristensen and K. Varming, *J. Extracell. Vesicles*, 2013, **2**, 20920.
- 63 G. Kim, C. E. Yoo, M. Kim, H. J. Kang, D. Park, M. Lee and N. Huh, *Bioconjugate Chem.*, 2012, **23**, 2114–2120.
- 64 C. Chen, B.-R. Lin, H.-K. Wang, S.-T. Fan, M.-Y. Hsu and C.-M. Cheng, *Microfluid. Nanofluid.*, 2014, **16**, 849–856.
- 65 M. He, J. Crow, M. Roth, Y. Zeng and A. K. Godwin, *Lab Chip*, 2014, **14**, 3773–3780.
- 66 S. Ibsen, A. Sonnenberg, C. Schutt, R. Mukthavaram, Y. Yeh, I. Ortac, S. Manouchehri, S. Kesari, S. Esener and M. J. Heller, *Small*, 2015, **11**, 5088–5096.
- 67 A. Sonnenberg, J. Y. Marciniak, E. A. Skowronski, S. Manouchehri, L. Rassenti, E. M. Ghia, G. F. Widhopf, T. J. Kipps and M. J. Heller, *Electrophoresis*, 2014, **35**, 1828–1836.
- 68 K. Kei, K. Masashi, H. Nami, A. Takanori, K. Nobuyoshi, O. Takahiro and I. Takanori, *Jpn. J. Appl. Phys.*, 2013, **52**, 06GK10.
- 69 E. J. van der Vlist, E. N. Nolte, W. Stoorvogel, G. J. Arkesteijn and M. H. Wauben, *Nat. Protoc.*, 2012, **7**, 1311–1326.
- 70 V. Sokolova, A.-K. Ludwig, S. Hornung, O. Rotan, P. A. Horn, M. Epple and B. Giebel, *Colloids Surf., B*, 2011, **87**, 146–150.
- 71 B. A. Ashcroft, J. de Sonnevile, Y. Yuana, S. Osanto, R. Bertina, M. E. Kuil and T. H. Oosterkamp, *Biomed. Microdevices*, 2012, **14**, 641–649.
- 72 C. Y. Soo, Y. Song, Y. Zheng, E. C. Campbell, A. C. Riches, F. Gunn-Moore and S. J. Powis, *Immunology*, 2012, **136**, 192–197.
- 73 C. Gardiner, Y. J. Ferreira, R. A. Dragovic, C. W. G. Redman and I. L. Sargent, *J. Extracell. Vesicles*, 2013, **2**, 19671.
- 74 C. Gercel-Taylor, S. Atay, R. H. Tullis, M. Kesimer and D. D. Taylor, *Anal. Biochem.*, 2012, **428**, 44–53.
- 75 A. Suetsugu, K. Honma, S. Saji, H. Moriwaki, T. Ochiya and R. M. Hoffman, *Adv. Drug Delivery Rev.*, 2013, **65**, 383–390.
- 76 N. Takeshita, I. Hoshino, M. Mori, Y. Akutsu, N. Hanari, Y. Yoneyama, N. Ikeda, Y. Isozaki, T. Maruyama and N. Akanuma, *Br. J. Cancer*, 2013, **108**, 644–652.
- 77 D. Marimpietri, A. Petretto, L. Raffaghello, A. Pezzolo, C. Gagliani, C. Tacchetti, P. Mauri, G. Melioli and V. Pistoia, *PLoS One*, 2013, **8**, e75054.
- 78 K. Sugimachi, T. Matsumura, H. Hirata, R. Uchi, M. Ueda, H. Ueo, Y. Shinden, T. Iguchi, H. Eguchi and K. Shirabe, *Br. J. Cancer*, 2015, **112**, 532–538.
- 79 H. Wang, L. Hou, A. Li, Y. Duan, H. Gao and X. Song, *BioMed Res. Int.*, 2014, **2014**, 864894.
- 80 C. Eicheler, I. Stückerath, V. Müller, K. Milde-Langosch, H. Wikman, K. Pantel and H. Schwarzenbach, *Oncotarget*, 2014, **5**, 9650.
- 81 B. Madhavan, S. Yue, U. Galli, S. Rana, W. Gross, M. Müller, N. A. Giese, H. Kalthoff, T. Becker and M. W. Büchler, *Int. J. Cancer*, 2015, **136**, 2616–2627.
- 82 X. Huang, T. Yuan, M. Liang, M. Du, S. Xia, R. Dittmar, D. Wang, W. See, B. A. Costello and F. Quevedo, *Eur. Urol.*, 2015, **67**, 33–41.
- 83 S. Robert, R. Lacroix, P. Poncelet, K. Harhour, T. Bouriche, C. Judicone, J. Wischhusen, L. Arnaud and F. Dignat-George, *Arterioscler., Thromb., Vasc. Biol.*, 2012, **32**, 1054–1058.
- 84 E. N. M. N.-t. Hoen, E. J. van der Vlist, M. Aalberts, H. C. H. Mertens, B. J. Bosch, W. Bartelink, E. Mastrobattista, E. V. B. van Gaal, W. Stoorvogel, G. J. A. Arkesteijn and M. H. M. Wauben, *Nanomedicine*, 2012, **8**, 712–720.



- 85 R. Lacroix, S. Robert, P. Poncelet and F. Dignat-George, *Semin. Thromb. Hemostasis*, 2010, **36**, 807–818.
- 86 D. L. M. Rupert, C. Lässer, M. Eldh, S. Block, V. P. Zhdanov, J. O. Lotvall, M. Bally and F. Höök, *Anal. Chem.*, 2014, **86**, 5929–5936.
- 87 R. Wyss, L. Grasso, C. Wolf, W. Grosse, D. Demurtas and H. Vogel, *Anal. Chem.*, 2014, **86**, 7229–7233.
- 88 D. Maiolo, L. Paolini, G. Di Noto, A. Zandrini, D. Berti, P. Bergese and D. Ricotta, *Anal. Chem.*, 2015, **87**, 4168–4176.
- 89 S. L. N. Maas, J. De Vrij and M. L. D. Broekman, *J. Visualized Exp.*, 2014, **92**, e51623.
- 90 R. Vaidyanathan, M. Naghibosadat, S. Rauf, D. Korbie, L. G. Carrascosa, M. J. A. Shiddiky and M. Trau, *Anal. Chem.*, 2014, **86**, 11125–11132.
- 91 A. Zomer, C. Maynard, F. J. Verweij, A. Kamermans, R. Schäfer, E. Beerling, R. M. Schiffelers, E. de Wit, J. Berenguer and S. I. J. Ellenbroek, *Cell*, 2015, **161**, 1046–1057.
- 92 S. A. Melo, L. B. Luecke, C. Kahlert, A. F. Fernandez, S. T. Gammon, J. Kaye, V. S. LeBleu, E. A. Mittendorf, J. Weitz and N. Rahbari, *Nature*, 2015, **523**, 177–182.
- 93 C. Lau, Y. Kim, D. Chia, N. Spielmann, G. Eibl, D. Elashoff, F. Wei, Y.-L. Lin, A. Moro and T. Grogan, *J. Biol. Chem.*, 2013, **288**, 26888–26897.
- 94 C. S. Hong, L. Muller, M. Boyiadzis and T. L. Whiteside, *PLoS One*, 2014, **9**, e103310.
- 95 K. Gabriel, A. Ingram, R. Austin, A. Kapoor, D. Tang, F. Majeed, T. Qureshi and K. Al-Nedawi, *PLoS One*, 2013, **8**, e70047.
- 96 C. J. Beckham, J. Olsen, P.-N. Yin, C.-H. Wu, H.-J. Ting, F. K. Hagen, E. Scosyrev, E. M. Messing and Y.-F. Lee, *J. Urol.*, 2014, **192**, 583–592.
- 97 E. Zerlinger, M. Li, T. Barta, J. Schageman, K. W. Pedersen, A. Neurauter, S. Magdaleno, R. Setterquist and A. V. Vlassov, *World J. Methodol.*, 2013, **3**, 11.
- 98 K. Ueda, N. Ishikawa, A. Tatsuguchi, N. Saichi, R. Fujii and H. Nakagawa, *Sci. Rep.*, 2014, **4**, 6232.

